Pathophysiology and management of inherited bone marrow failure syndromes

Blood Reviews

Volumn 24, Issue 3, 2010, Pages 101-122

  Shimamura, Akiko ^a   Alter, Blanche P ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Aplastic anemia; Diamond Blackfan anemia; Dyskeratosis congenita; Fanconi; Inherited bone marrow failure syndromes; Shwachman Diamond syndrome

Indexed keywords

AMINOCAPROIC ACID; ANDROGEN; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 3; LEUCINE; METOCLOPRAMIDE; OXYMETHOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 3; TRANEXAMIC ACID; VALPROIC ACID;

ADRENAL INSUFFICIENCY; AMEGAKARYOCYTIC THROMBOCYTOPENIA; APLASIA; APLASTIC ANEMIA; BEHAVIOR DISORDER; BLACKFAN DIAMOND ANEMIA; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOPENIA; DIABETES MELLITUS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSKERATOSIS CONGENITA; EPIPHYSIS DISEASE; FANCONI ANEMIA; GENETIC DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC SYSTEM; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMMUNE DEFICIENCY; INHERITANCE; LIVER TUMOR; MOLECULAR BIOLOGY; MOOD DISORDER; MYELOABLATIVE CONDITIONING; NEUTROPENIA; OBSTRUCTIVE JAUNDICE; PATHOGENESIS; PEARSON SYNDROME; PELIOSIS HEPATIS; PHENOTYPE; PREMATURE EPIPHYSEAL CLOSURE; PRIORITY JOURNAL; RADIOULNA SYNOSTOSIS; REVIEW; SEVERE CONGENITAL NEUTROPENIA; SHWACHMAN SYNDROME; SIDE EFFECT; SPLEEN DISEASE; SPLEEN RUPTURE; SPLENIC PELIOSIS; THROMBOCYTOPENIA; THROMBOCYTOPENIA ABSENT RADII; UNSPECIFIED SIDE EFFECT; VIRILIZATION; WEIGHT GAIN;

BONE MARROW DISEASES; GENETIC DISEASES, INBORN; HUMANS; SYNDROME;

EID: 77952674566     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.03.002     Document Type: Review

References (155)

1. Bagby G.C., Meyers G. Bone marrow failure syndromes. Preface. Hematol Oncol Clin North Am 2009, 23:xiii-xiv.
2. Tsilou E.T., Giri N., Weinstein S., Mueller C., Savage S.A., Alter B.P. Ocular and orbital manifestations of the inherited bone marrow failure syndromes: fanconi anemia and dyskeratosis congenita. Ophthalmology 2010, 117(3):615-622.
3. Johnson MA, Olson S, Alter BP, Giri N, Hogan WJ, Richards CS. An unusual case of Fanconi Anemia with adult onset, mosaicism in an asymptomatic sibling, and a possible molecular explanation. Presented at the 59th Annual Meeting of the American Society of Human Genetics, October 24th, 2009, Honolulu, Hawaii.
4. Auerbach A.D., Adler B., Chaganti R.S. Prenatal and postnatal diagnosis and carrier detection of Fanconi anemia by a cytogenetic method. Pediatrics 1981, 67:128-135.
5. Ameziane N., Errami A., Leveille F., Fontaine C., de Vries Y., van Spaendonk R.M., et al. Genetic subtyping of Fanconi anemia by comprehensive mutation screening. Hum Mutat 2008, 29:159-166.
6. Alter B.P., Joenje H., Oostra A.B., Pals G. Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. Arch Otolaryngol Head Neck Surg 2005, 131:635-639.
7. Rosenberg P.S., Huang Y., Alter B.P. Individualized risks of first adverse events in patients with Fanconi anemia. Blood 2004, 104:350-355.
8. Rosenberg P.S., Socie G., Alter B.P., Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood 2005, 105:67-73.
9. Alter B.P., Rosenberg P.S., Brody L.C. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 2007, 44:1-9.
10. Alter B., Frissora C., et al. Fanconi's anemia and pregnancy. Br J Haematol 1991, 77:410-418.
11. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748.
12. de Winter J.P., Joenje H. The genetic and molecular basis of Fanconi anemia. Mutat Res 2009, 668:11-19.
13. Green A.M., Kupfer G.M. Fanconi anemia. Hematol Oncol Clin North Am 2009, 23:193-214.
14. Moldovan G.L., D'Andrea A.D. How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009, 43:223-249.
15. Andreassen P.R., D'Andrea A.D., Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004, 18:1958-1963.
16. Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., Kim S.T., et al. Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002, 109:459-472.
17. Nakanishi K., Taniguchi T., Ranganathan V., New H.V., Moreau L.A., Stotsky M., et al. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol 2002, 4:913-920.
18. Meetei A.R., Sechi S., Wallisch M., Yang D., Young M.K., Joenje H., et al. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol 2003, 23:3417-3426.
19. Pichierri P., Franchitto A., Rosselli F. BLM and the FANC proteins collaborate in a common pathway in response to stalled replication forks. EMBO J 2004, 23:3154-3163.
20. Fagerlie S., Lensch M.W., Pang Q., Bagby G.C. The Fanconi anemia group C gene product: signaling functions in hematopoietic cells. Exp Hematol 2001, 29:1371-1381.
21. Bagby G.C., Alter B.P. Fanconi anemia. Semin Hematol 2006, 43:147-156.
22. Tonnies H., Huber S., Kuhl J.S., Gerlach A., Ebell W., Neitzel H. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood 2003, 101:3872-3874.
23. Shimamura A. Treatment of hematologic abnormalities in Fanconi anemia. Fanconi anemia guidelines for diagnosis and management 2008, 49-75. Fanconi Anemia Research Fund, Eugene. 3rd Edition. M.E. Eiler, D. Frohnmayer, L. Frohnmayer, K. Larsen, J. Owen (Eds.).
24. Gluckman E., Devergie A., Schaison G., Bussel A., Berger R., Sohier J., et al. Bone marrow transplantation in Fanconi anaemia. Br J Haematol 1980, 45:557-564.
25. Gluckman E., Wagner J.E. Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome. Bone Marrow Transplant 2008, 41:127-132.
26. Myers K.C., Davies S.M. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant 2009, 15:279-292.
27. Wagner J.E., Eapen M., MacMillan M.L., Harris R.E., Pasquini R., Boulad F., et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007, 109:2256-2262.
28. Deeg H.J., Socie G., Schoch G., Henry-Amar M., Witherspoon R.P., Devergie A., et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996, 87:386-392.
29. Guardiola P., Socie G., Li X., Ribaud P., Devergie A., Esperou H., et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood 2004, 103:73-77.
30. Velazquez I., Alter B.P. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 2004, 77:257-267.
31. Kutler D.I., Wreesmann V.B., Goberdhan A., Ben-Porat L., Satagopan J., Ngai I., et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003, 95:1718-1721.
32. van Zeeburg H.J., Snijders P.J., Wu T., Gluckman E., Soulier J., Surralles J., et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2008, 100:1649-1653.
33. Al-Rahawan M.M., Giri N., Alter B.P. Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita. Int J Hematol 2006, 83:275-276.
34. Rosenberg P.S., Giri N., Savage S.A., BP A. Cancer epidemiology in the National Cancer Institute inherited bone marrow failure syndromes cohort: first report 2008, American Society of Hematology, American Society of Hematology.
35. Vulliamy T.J., Marrone A., Knight S.W., Walne A., Mason P.J., Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006, 107:2680-2685.
36. Savage S.A., Alter B.P. Dyskeratosis congenita. Hematol Oncol Clin North Am 2009, 23:215-231.
37. Armanios M.Y., Chen J.J., Cogan J.D., Alder J.K., Ingersoll R.G., Markin C., et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007, 356:1317-1326.
38. Alter B.P., Caruso J.P., Drachtman R.A., Uchida R., Velagaleti G.V.N., Elghetany M.T. Fanconi anemia: myelodysplasia as a predictor of outcome. Cancer Genet Cytogenet 2000, 117:125-131.
39. Alter B.P., Baerlocher G.M., Savage S.A., Chanock S.J., Weksler B.B., Willner J.P., et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007, 110:1439-1447.
40. Du H.Y., Pumbo E., Ivanovich J., An P., Maziarz R.T., Reiss U.M., et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 2009, 113:309-316.
41. Walne A.J., Dokal I. Advances in the understanding of dyskeratosis congenita. Br J Haematol 2009, 145:164-172.
42. Kirwan M., Dokal I. Dyskeratosis congenita, stem cells and telomeres. Biochim Biophys Acta 2009, 1792:371-379.
43. Marrone A., Walne A., Tamary H., Masunari Y., Kirwan M., Beswick R., et al. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood 2007, 110:4198-4205.
44. Du H.Y., Pumbo E., Manley P., Field J.J., Bayliss S.J., Wilson D.B., et al. Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene. Blood 2008, 111:1128-1130.
45. Vulliamy T., Marrone A., Szydlo R., Walne A., Mason P.J., Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004, 36:447-449.
46. Armanios M., Chen J.L., Chang Y.P., Brodsky R.A., Hawkins A., Griffin C.A., et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A 2005, 102:15960-15964.
47. Yamaguchi H., Baerlocher G.M., Lansdorp P.M., Chanock S.J., Nunez O., Sloand E., et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003, 102:916-918.
48. Vulliamy T.J., Walne A., Baskaradas A., Mason P.J., Marrone A., Dokal I. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 2005, 34:257-263.
49. Yamaguchi H., Calado R.T., Ly H., Kajigaya S., Baerlocher G.M., Chanock S.J., et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005, 352:1413-1424.
50. Tsakiri K.D., Cronkhite J.T., Kuan P.J., Xing C., Raghu G., Weissler J.C., et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 2007, 104:7552-7557.
51. Alder J.K., Chen J.J., Lancaster L., Danoff S., Su S.C., Cogan J.D., et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 2008, 105:13051-13056.
52. Savage S.A., Giri N., Baerlocher G.M., Orr N., Lansdorp P.M., Alter B.P. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008, 82:501-509.
53. Walne A.J., Vulliamy T., Beswick R., Kirwan M., Dokal I. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 2008, 112:3594-3600.
54. Shimamura A. Inherited bone marrow failure syndromes: molecular features. Hematol Am Soc Hematol Educ Program 2006, 63-71.
55. Meier U.T. The many facets of H/ACA ribonucleoproteins. Chromosoma 2005, 114:1-14.
56. King T.H., Liu B., McCully R.R., Fournier M.J. Ribosome structure and activity are altered in cells lacking snoRNPs that form pseudouridines in the peptidyl transferase center. Mol Cell 2003, 11:425-435.
57. Mochizuki Y., He J., Kulkarni S., Bessler M., Mason P.J. Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl Acad Sci U S A 2004, 101:10756-10761.
58. Ruggero D., Grisendi S., Piazza F., Rego E., Mari F., Rao P.H., et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003, 299:259-262.
59. Yoon A., Peng G., Brandenburg Y., Zollo O., Xu W., Rego E., et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006, 312:902-906.
60. Berthou C., Devergi A., D'Agay M.F., Sonsino E., Scrobohaci M.L., Loirat C., et al. Late vascular complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1991, 79:335-336.
61. Fogarty P.F., Yamaguchi H., Wiestner A., Baerlocher G.M., Sloand E., Zeng W.S., et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003, 362:1628-1630.
62. Alter B.P., Gardner E.H., Hall R.E. Treatment of dyskeratosis congenita with granulocyte macrophage colony-stimulating factor and erythropoietin. Br J Haematol 1997, 97:309-311.
63. Giri N., Pitel P.A., Green D., Alter B.P. Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor. Br J Haematol 2007, 138:815-817.
64. Fanconi Anemia Research Fund I Guidelines for diagnosis and management 2008, Fanconi Anemia Research Fund, Inc., Eugene, OR.
65. Balaban E.P., Buchanan G.R., Graham M., Frenkel E.P. Diamond-Blackfan syndrome in adult patients. Am J Med 1985, 78:533-538.
66. Lipton J.M., Ellis S.R. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am 2009, 23:261-282.
67. Matsson H., Davey E.J., Draptchinskaia N., Hamaguchi I., Ooka A., Leveen P., et al. Targeted disruption of the ribosomal protein S19 gene is lethal prior to implantation. Mol Cell Biol 2004, 24:4032-4037.
68. McGowan K.A., Li J.Z., Park C.Y., Beaudry V., Tabor H.K., Sabnis A.J., et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet 2008, 40:963-970.
69. Danilova N., Sakamoto K.M., Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood 2008, 112:5228-5237.
70. Uechi T., Nakajima Y., Chakraborty A., Torihara H., Higa S., Kenmochi N. Deficiency of ribosomal protein S19 during early embryogenesis leads to reduction of erythrocytes in a zebrafish model of Diamond-Blackfan anemia. Hum Mol Genet 2008, 17:3204-3211.
71. Dianzani I., Loreni F. Diamond-Blackfan anemia: a ribosomal puzzle. Haematologica 2008, 93:1601-1604.
72. Ellis S.R., Lipton J.M. Diamond Blackfan anemia: a disorder of red blood cell development. Curr Top Dev Biol 2008, 82:217-241.
73. Jin A., Itahana K., O'Keefe K., Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 2004, 24:7669-7680.
74. Dai M.S., Zeng S.X., Jin Y., Sun X.X., David L., Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 2004, 24:7654-7668.
75. Marechal V., Elenbaas B., Piette J., Nicolas J.C., Levine A.J. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol 1994, 14:7414-7420.
76. Lohrum M.A., Ludwig R.L., Kubbutat M.H., Hanlon M., Vousden K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003, 3:577-587.
77. Zhang Y., Wolf G.W., Bhat K., Jin A., Allio T., Burkhart W.A., et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 2003, 23:8902-8912.
78. Fumagalli S., Di Cara A., Neb-Gulati A., Natt F., Schwemberger S., Hall J., et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol 2009, 11:501-508.
79. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
80. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89:739-761.
81. Roggero S., Quarello P., Vinciguerra T., Longo F., Piga A., Ramenghi U. Severe iron overload in Blackfan-Diamond anemia: a case-control study. Am J Hematol 2009, 84:729-732.
82. Shwachman H., Diamond L.K., Oski F.A., Khaw K.T. The syndrome of pancreatic insufficiency and bone marrow dysfunction. J Pediatr 1964, 65:645-663.
83. Rothbaum R., Perrault J., Vlachos A., Cipolli M., Alter B.P., Burroughs S., et al. Shwachman-Diamond syndrome: report from an international conference. J Pediatr 2002, 141:266-270.
84. Savilahti E., Rapola J. Frequent myocardial lesions in Shwachman's syndrome. Eight fatal cases among 16 Finnish patients. Acta Paediatr Scand 1984, 73:642-651.
85. Alter B.P., Kumar M., Lockhart L.L., Sprinz P.G., Rowe T.F. Pregnancy in bone marrow failure syndromes: Diamond-Blackfan anaemia and Shwachman-Diamond syndrome. Br J Haematol 1999, 107:49-54.
86. Boocock G.R., Morrison J.A., Popovic M., Richards N., Ellis L., Durie P.R., et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 2003, 33:97-101.
87. Zhang S., Shi M., Hui C.C., Rommens J.M. Loss of the mouse ortholog of the Shwachman-Diamond syndrome gene (sbds) results in early embryonic lethality. Mol Cell Biol 2006, 26:6656-6663.
88. Savchenko A., Krogan N., Cort J.R., Evdokimova E., Lew J.M., Yee A.A., et al. The Shwachman-Bodian-Diamond syndrome protein family is involved in RNA metabolism. J Biol Chem 2005, 280:19213-19220.
89. Shammas C., Menne T.F., Hilcenko C., Michell S.R., Goyenechea B., Boocock G.R., et al. Structural and mutational analysis of the SBDS protein family: insight into the leukemia-associated Shwachman-Diamond syndrome. J Biol Chem 2005, 280:19221-19229.
90. Ganapathi K.A., Austin K.M., Lee C.S., Dias A., Malsch M.M., Reed R., et al. The human Shwachman-Diamond syndrome protein, SBDS, associates with ribosomal RNA. Blood 2007, 110:1458-1465.
91. Ng C.L., Waterman D.G., Koonin E.V., Walters A.D., Chong J.P., Isupov M.N., et al. Conformational flexibility and molecular interactions of an archaeal homologue of the Shwachman-Bodian-Diamond syndrome protein. BMC Struct Biol 2009, 9:32.
92. Luz J.S., Georg R.C., Gomes C.H., Machado-Santelli G.M., Oliveira C.C. Sdo1p, the yeast orthologue of Shwachman-Bodian-Diamond syndrome protein, binds RNA and interacts with nuclear rRNA-processing factors. Yeast 2009, 26:287-298.
93. Rujkijyanont P., Adams S.L., Beyene J., Dror Y. Bone marrow cells from patients with Shwachman-Diamond syndrome abnormally express genes involved in ribosome biogenesis and RNA processing. Br J Haematol 2009, 145:806-815.
94. Basu U., Si K., Warner J.R., Maitra U. The Saccharomyces cerevisiae TIF6 gene encoding translation initiation factor 6 is required for 60S ribosomal subunit biogenesis. Mol Cell Biol 2001, 21:1453-1462.
95. Ceci M., Gaviraghi C., Gorrini C., Sala L.A., Offenhauser N., Marchisio P.C., et al. Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature 2003, 426:579-584.
96. Moore J.B., Farrar J.E., Arceci R.J., Liu J.M., Ellis S.R. Distinct ribosome maturation defects in yeast models of Diamond-Blackfan anemia and Shwachman-Diamond syndrome. Haematologica 2010 Jan, 95(1):57-64.
97. Austin K.M., Gupta M.L., Coats S.A., Tulpule A., Mostoslavsky G., Balazs A.B., et al. Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome. J Clin Invest 2008, 118:1511-1518.
98. Orelio C., Verkuijlen P., Geissler J., van den Berg T.K., Kuijpers T.W. SBDS expression and localization at the mitotic spindle in human myeloid progenitors. PLoS One 2009, 4:e7084.
99. Maserati E., Pressato B., Valli R., Minelli A., Sainati L., Patitucci F., et al. The route to development of myelodysplastic syndrome/acute myeloid leukaemia in Shwachman-Diamond syndrome: the role of ageing, karyotype instability, and acquired chromosome anomalies. Br J Haematol 2009, 145:190-197.
100. Dror Y., Freedman M.H. Shwachman-Diamond syndrome: an inherited preleukemic bone marrow failure disorder with aberrant hematopoietic progenitors and faulty marrow microenvironment. Blood 1999, 94:3048-3054.
101. Rawls A., Gregory A., Wolosznek J., Liu F., Link D. Lentiviral-mediated RNAi inhibition of Sbds in murine hematopoietic progenitors impairs their hematopoietic potential. Blood 2007, 110:2414-2422.
102. Watanabe K., Ambekar C., Wang H., Ciccolini A., Schimmer A.D., Dror Y. SBDS-deficiency results in specific hypersensitivity to Fas stimulation and accumulation of Fas at the plasma membrane. Apoptosis 2009, 14:77-89.
103. Ball H.L., Zhang B., Riches J.J., Gandhi R., Li J., Rommens J.M., et al. Shwachman-Bodian-Diamond syndrome is a multi-functional protein implicated in cellular stress responses. Hum Mol Genet 2009, 18:3684-3695.
104. Dror Y., Ginzberg H., Dalal I., Cherepanov V., Downey G., Durie P., et al. Immune function in patients with Shwachman-Diamond syndrome. Br J Haematol 2001, 114:712-717.
105. Orelio C., Kuijpers T.W. Shwachman-Diamond syndrome neutrophils have altered chemoattractant-induced F-actin polymerization and polarization characteristics. Haematologica 2009, 94:409-413.
106. Grinspan Z.M., Pikora C.A. Infections in patients with Shwachman-Diamond syndrome. Pediatr Infect Dis J 2005, 24:179-181.
107. Rosenberg P.S., Alter B.P., Bolyard A.A., Bonilla M.A., Boxer L.A., Cham B., et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006, 107:4628-4635.
108. Rosenberg P.S., Alter B.P., Link D.C., Stein S., Rodger E., Bolyard A.A., et al. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol 2008, 140:210-213.
109. Burroughs L., Woolfrey A., Shimamura A. Shwachman-Diamond syndrome: a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment. Hematol Oncol Clin North Am 2009, 23:233-248.
110. Cesaro S., Oneto R., Messina C., Gibson B.E., Buzyn A., Steward C., et al. Haematopoietic stem cell transplantation for Shwachman-Diamond disease: a study from the European Group for blood and marrow transplantation. Br J Haematol 2005, 131:231-236.
111. Donadieu J., Michel G., Merlin E., Bordigoni P., Monteux B., Beaupain B., et al. Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: experience of the French neutropenia registry. Bone Marrow Transplant 2005, 36:787-792.
112. Bhatla D., Davies S.M., Shenoy S., Harris R.E., Crockett M., Shoultz L., Smolarek T., Bleesing J., Hansen M., Jodele S., Jordan M., Filipovich A.H., Mehta P.A. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant 2008 Aug, 42(3):159-165.
113. Dale D.C., Bolyard A.A., Schwinzer B.G., Pracht G., Bonilla M.A., Boxer L., et al. The severe chronic neutropenia international registry: 10-year follow-up report. Support Cancer Ther 2006, 3:220-231.
114. Welte K., Zeidler C. Severe congenital neutropenia. Hematol Oncol Clin North Am 2009, 23:307-320.
115. Dale D.C., Person R.E., Bolyard A.A., Aprikyan A.G., Bos C., Bonilla M.A., et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000, 96:2317-2322.
116. Kollner I., Sodeik B., Schreek S., Heyn H., von Neuhoff N., Germeshausen M., et al. Mutations in neutrophil elastase causing congenital neutropenia lead to cytoplasmic protein accumulation and induction of the unfolded protein response. Blood 2006, 108:493-500.
117. Grenda D.S., Murakami M., Ghatak J., Xia J., Boxer L.A., Dale D., et al. Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis. Blood 2007, 110:4179-4187.
118. Xia J., Link D.C. Severe congenital neutropenia and the unfolded protein response. Curr Opin Hematol 2008, 15:1-7.
119. Klein C., Grudzien M., Appaswamy G., Germeshausen M., Sandrock I., Schaffer A.A., et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007, 39:86-92.
120. Devriendt K., Kim A.S., Mathijs G., Frints S.G., Schwartz M., Van Den Oord J.J., et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001, 27:313-317.
121. Ancliff P.J., Blundell M.P., Cory G.O., Calle Y., Worth A., Kempski H., et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 2006, 108:2182-2189.
122. Moulding D.A., Blundell M.P., Spiller D.G., White M.R., Cory G.O., Calle Y., et al. Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. J Exp Med 2007, 204:2213-2224.
123. Ochs H.D., Thrasher A.J. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006, 117:725-738. quiz 739.
124. Person R.E., Li F.Q., Duan Z., Benson K.F., Wechsler J., Papadaki H.A., et al. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nat Genet 2003, 34:308-312.
125. Karsunky H., Zeng H., Schmidt T., Zevnik B., Kluge R., Schmid K.W., et al. Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1. Nat Genet 2002, 30:295-300.
126. Hock H., Hamblen M.J., Rooke H.M., Traver D., Bronson R.T., Cameron S., et al. Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity 2003, 18:109-120.
127. Hock H., Orkin S.H. Zinc-finger transcription factor Gfi-1: versatile regulator of lymphocytes, neutrophils and hematopoietic stem cells. Curr Opin Hematol 2006, 13:1-6.
128. Kazanjian A., Gross E.A., Grimes H.L. The growth factor independence-1 transcription factor: new functions and new insights. Crit Rev Oncol Hematol 2006, 59:85-97.
129. Velu C.S., Baktula A.M., Grimes H.L. Gfi1 regulates miR-21 and miR-196b to control myelopoiesis. Blood 2009, 113:4720-4728.
130. Boztug K., Appaswamy G., Ashikov A., Schaffer A.A., Salzer U., Diestelhorst J., et al. A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J Med 2009, 360:32-43.
131. Germeshausen M., Ballmaier M., Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey. Blood 2007, 109:93-99.
132. Link D.C., Kunter G., Kasai Y., Zhao Y., Miner T., McLellan M.D., et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood 2007, 110:1648-1655.
133. Boztug K., Klein C. Novel genetic etiologies of severe congenital neutropenia. Curr Opin Immunol 2009, 21:472-480.
134. Dale D.C., Bonilla M.A., Davis M.W., Nakanishi A.M., Hammond W.P., Kurtzberg J., et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993, 81:2496-2502.
135. Zeidler C., Welte K., Barak Y., Barriga F., Bolyard A.A., Boxer L., et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood 2000, 95:1195-1198.
136. Germeshausen M., Ballmaier M., Welte K. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mutat 2006, 27:296-301.
137. Ihara K., Ishii E., Eguchi M., Takada H., Suminoe A., Good R.A., et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 1999, 96:3132-3136.
138. Kaushansky K., Lok S., Holly R.D., Broudy V.C., Lin N., Bailey M.C., et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994, 369:568-571.
139. Bartley T.D., Bogenberger J., Hunt P., Li Y.S., Lu H.S., Martin F., et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994, 77:1117-1124.
140. Gurney A.L., Carver-Moore K., de Sauvage F.J., Moore M.W. Thrombocytopenia in c-mpl-deficient mice. Science 1994, 265:1445-1447.
141. Alexander W.S., Roberts A.W., Nicola N.A., Li R., Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996, 87:2162-2170.
142. King S., Germeshausen M., Strauss G., Welte K., Ballmaier M. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol 2005, 131:636-644.
143. Ballmaier M., Germeshausen M., Schulze H., Cherkaoui K., Lang S., Gaudig A., et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001, 97:139-146.
144. Savoia A., Dufour C., Locatelli F., Noris P., Ambaglio C., Rosti V., et al. Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica 2007, 92:1186-1193.
145. Ballmaier M., Germeshausen M. Advances in the understanding of congenital amegakaryocytic thrombocytopenia. Br J Haematol 2009, 146:3-16.
146. Geddis A.E. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Hematol Oncol Clin North Am 2009, 23:321-331.
147. Guinan E.C., Lee Y.S., Lopez K.D., Kohler S., Oette D.H., Bruno E., et al. Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood 1993, 81:1691-1698.
148. Thompson A.A., Woodruff K., Feig S.A., Nguyen L.T., Schanen N.C. Congenital thrombocytopenia and radio-ulnar synostosis: a new familial syndrome. Br J Haematol 2001, 113:866-870.
149. Oblender M.G., Richardson C.J., Alter B.P. Pearson syndrome (PS) presenting as nonimmune hydrops fetalis. Clin Res 1993, 41.
150. Fleming W.H., Trounce I., N.K., et al. Cytokine treatment improves the hematologic manifestations of Pearson's syndrome. Blood Cells Mol Dis 1994, 84.
151. Hoyoux C., Dresse M.F., Robinet S., Forget P., Pieltain C., Ketelslegers O., et al. Cord blood transplantation in a child with Pearson's disease. Pediatr Blood Cancer 2008, 51:566.
152. DiMauro S., Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep 2007, 27:125-137.
153. Alter B.P. Inherited bone marrow failure syndromes. Nathan and Oski's hematology of infancy and childhood 2003, Vol. 1:280-365. W.B. Saunders, Philadelphia.
154. Leiden Open Variation Database: Fanconi anemia database: Leiden University Medical Center 2009.
155. Online Mendelian Inheritance in Man, OMIM (TM) ®: McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, National Center for Biotechnology Information, National Library of Medicine; 2009.